<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117234</url>
  </required_header>
  <id_info>
    <org_study_id>20020126</org_study_id>
    <nct_id>NCT00117234</nct_id>
  </id_info>
  <brief_title>Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia</brief_title>
  <official_title>A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on
      peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>July 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance, measured as peak VO(subscript)2</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise duration; *NYHA classification; *Patient-reported outcomes</measure>
  </secondary_outcome>
  <condition>Congestive Heart Failure</condition>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular
        ejection fraction - Stable heart failure medication - Peak VO2 less than or equal to 16
        ml/kg/min - Hemoglobin concentration between 9.0 and 12.0 g/dL Exclusion Criteria: -
        Hypertension - Unstable angina pectoris or recent myocardial infarction - Likely to receive
        cardiac transplant - Unable to do cardiopulmonary exercise testing - Major organ transplant
        (e.g., lung, liver, heart) or renal replacement therapy (e.g., dialysis) - Recent or
        current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or
        chronic bleeding - Recent EpogenÂ® or darbepoetin alfa therapy - Recent blood transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2005</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>chronic heart failure</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>low hemoglobin</keyword>
  <keyword>anemia</keyword>
  <keyword>CHF</keyword>
  <keyword>Symptomatic Congestive Heart Failure (CHF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

